The platforms are distinct but the end game is identical. Rare disease company Allena Pharmaceuticals Inc., anti-infectives developer Spero Therapeutics LLC and cancer therapy hopeful Erytech Pharma SA filed for U.S. IPOs, joining Ablynx NV, which filed days earlier, to extend the biopharma trek to the public markets into the fourth quarter.